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Introduction: Depressive episodes are often prevalent among patients with bipolar 
disorder, but little is known regarding the differential patterns of development over 
time. We aimed to determine and characterize trajectories of depressive symptoms 
among adults with bipolar disorder during 6 months of systematic treatment.
Methods: The pragmatic clinical trial, Bipolar Clinical Health Outcomes Initiative in 
Comparative Effectiveness (CHOICE), randomized 482 outpatients with bipolar dis‐
order to lithium or quetiapine. Depressive symptoms were rated at up to 9 visits 
using the Montgomery‐Asberg Depression Rating Scale (MADRS). Growth mixture 
modeling was utilized to identify trajectories and multinomial regression analysis es‐
timated associations with potential predictors.
Results: Four distinct trajectories of depressive symptoms were identified. The re‐
sponding class (60.3%) with a rapid reduction and subsequent low level; the 
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1  | INTRODUC TION
Bipolar disorder has a negative impact on the patient’s quality of 
life, with depressive symptoms having a particularly strong effect 
on their well‐being. The unpredictable nature of the illness makes 
it challenging to treat efficiently and despite state‐of‐the‐art treat‐
ment, many patients do not respond sufficiently and have symptoms 
approximately 50% of the time.1 Furthermore, the medical treatment 
with mood stabilizers and antipsychotics is associated with severe 
side‐effects and antidepressants can cause manic switches.1,2 Only 
little is known regarding symptom development in patients with bi‐
polar disorder, and it is therefore highly relevant to investigate this 
aspect to gain more knowledge of the illness and whether similari‐
ties exist between this patient group and patients with unipolar de‐
pression. Furthermore, the medical treatment of bipolar depression 
differs from the treatment of unipolar depression and it is therefore 
important to investigate treatment response of the medical treat‐
ment used in bipolar depression.
Longitudinal follow‐up studies have found that bipolar disorder is 
chronic and dominated by depressive episodes rather than manic or 
hypomanic episodes.1,3,4 Therefore, better treatment of depressive 
symptoms represents one of the main challenges in the treatment of 
patients with bipolar disorder.5,6 Further research is of great clinical 
importance and could potentially contribute to a more personalized 
and improved treatment.
Recently, group‐based trajectory models have gained much 
traction because of their usefulness when studying heterogeneity 
in symptom development. In these models, underlying subgroups 
within a population are identified and a growth curve for each sub‐
group is estimated.7,8 Several studies have examined trajectories of 
depressive symptoms and found symptom development to be highly 
heterogeneous.9‐19 However, these studies were either conducted 
among the general population9‐12,14,15 or among patients suffering 
from unipolar depressive disorder.16‐19 Only few clinical studies have 
performed trajectory analyses to explore symptom development 
among patients with bipolar disorder, and none of these have inves‐
tigated how depressive symptoms improve over time.20‐22 Hence, 
the primary purpose of this study was to estimate trajectories of de‐
pressive symptoms among outpatients with diagnosed bipolar disor‐
der to examine, if patients could be classified into subgroups, where 
they shared similar patterns of depressive symptom improvement. 
Our secondary aim was to investigate if specific covariates predicted 
membership of the identified trajectory classes.
2  | METHOD
2.1 | Data source
Data were obtained from the Bipolar Clinical Health Outcomes 
Initiative in Comparative Effectiveness (CHOICE) study.23 Bipolar 
CHOICE was a pragmatic 6‐month randomized controlled multisite 
trial comparing treatment with lithium to treatment with quetiapine 
among outpatients diagnosed with bipolar disorder type I (68.3%) 
or type II (31.7%) according to DSM‐IV‐TR criteria.24 Participants 
had to be 18 years or older and at least mildly symptomatic at inclu‐
sion time with a Clinical Global Impression scale for bipolar disor‐
der (CGI‐BP) score ≥3.25 Participants were excluded if they had any 
contraindication to lithium or quetiapine, were in a crisis (eg, inpa‐
tient hospitalization), or if they were currently treated with lithium 
or quetiapine. A total of 692 outpatients with bipolar disorder were 
screened and 482 patients met the inclusion criteria and were ran‐
domized to either lithium (240 patients) or quetiapine (242 patients) 
along with adjunctive personalized treatment (APT) (except lithium 
and quetiapine). Demographics and clinical features were monitored 
among participants at baseline and found to be similar between the 
two randomized groups.26
partial‐responding class (18.4%) with an initial reduction followed by an increase dur‐
ing the remaining weeks; the fluctuating class (11.6%) with a fluctuation in depressive 
symptoms; and the non‐responding class (9.7%) with sustained moderate‐severe de‐
pressive symptoms. Bipolar type I predicted membership of the non‐responding class 
and randomization to quetiapine predicted membership of either the responding or 
the non‐responding class.
Conclusion: Approximately 30% experienced a partial or fluctuating course, and al‐
most 10% had a chronic course with moderate‐severe depression during 6 months. 
Patients diagnosed with bipolar type 1 had higher risk of being categorized into a 
class with a worse outcome. While no differences in average overall outcomes oc‐
curred between the lithium and quetiapine groups, trajectory analysis revealed that 
the lithium group had more variable courses.
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The study took place at 11 sites in the United States and was con‐
ducted from September 2010 to September 2013. At study entry, 
trained clinical research coordinators collected sociodemographic 
and clinical information and the symptomatology was closely mon‐
itored with several rating scales both at baseline and during eight 
follow‐up visits at week: 2, 4, 6, 8, 12, 16, 20, and 24. The study 
was approved by the Institutional Review Boards at all sites, and all 
participants signed approved informed consent forms prior to initia‐
tion of the trial. Further details about the study design are described 
elsewhere.23
2.2 | Outcome measure
Depressive symptoms were assessed using the Montgomery‐Asberg 
Depression Rating Scale (MADRS), a well‐established ten item rating 
scale measuring the overall severity of depressive symptoms ranging 
from 0 to 60.27 We chose this scale due it previously having shown 
a high reliability when measuring depressive symptoms among pa‐
tients with unipolar depression.28 The following cutoff values were 
used to grade depressive symptoms severity: 0‐6: symptoms ab‐
sent; 7‐19: mild depression; 20‐34: moderate depression; ≥35: se‐
vere depression.29 Criteria for treatment remission were defined as 
a MADRS score ≤12 at the last follow‐up visit, and treatment re‐
sponse was defined as a MADRS score reduction ≥50% measured 
from baseline to the last follow‐up visit.
2.3 | Predictors
We included the following sociodemographic and clinical covariates 
assessed at study entry in the predictor analysis: sex, age, age at 
first manic episode (if appropriate), age at first depressive episode, 
ethnicity (Caucasian/other), education (high school or less/college 
or more), employment (employed or student/not employed), type of 
bipolar disorder (type 1/type 2), CGI mania score at baseline, history 
of psychiatric hospitalization, history of suicide attempt, any current 
anxiety disorder, current diagnosis of posttraumatic stress disorder 
(PTSD), level of psychotic symptoms at baseline, family history of 
mental illness (schizophrenia, bipolar disorder or unipolar depression 
among first‐line relatives) comorbidities (diabetes, hypertension, hy‐
perlipidaemia), history of suicide attempts in the family (parents, sib‐
lings or children), treatment arm (lithium/quetiapine), alcohol abuse 
within the last 12 months, lifetime alcohol abuse, any substance 
abuse within the last 12 months, and any lifetime substance abuse.
2.4 | Statistical analysis
All models were estimated in Mplus editor version 7.2.
We used growth mixture modeling (GMM) to estimate trajecto‐
ries of depressive symptoms.7,8 This is a data‐driven person‐centered 
approach, where subgroups within the population are identified 
based on prototypical patterns in slope and intercepts.8 In that way, 
a growth curve for each subgroup is estimated and variation within 
each subgroup is allowed.7,8,30
We first estimated latent class analysis and latent growth curve 
models (LGCM) to check whether it appeared that subgroups within 
the population actually existed. We then estimated longitudinal class 
growth analysis (LCGA) and GMM models with different growth 
functions (ie, linear, quadratic, or cubic) and with increasing number 
of classes. All models with an entropy below 0.7 and models that 
could not converge were excluded hence doubting the validity of 
the estimated models.
When comparing the different models, we examined fit estimates 
(Bayesian information criterion [BIC]; adjusted BIC, and Akaike infor‐
mation criterion [AIC]) where lower fit estimates indicated a better 
fit of data. Furthermore, we looked at class sizes, entropy, poste‐
rior probabilities for classification accuracy, clinical utility, and the 
bootstrap log‐likelihood test which tests whether the model with n 
number of classes is a significantly better fit of data compared to a 
model with n‐1 number of classes.7
After deciding on the final model, we included all covariates to 
test their association with the identified trajectories. We used an 
explorative approach when performing the predictor analysis. We 
applied a three‐step approach which takes into account classifica‐
tion error.31 When using this approach, the pre‐defined covariates 
did not influence the formation of the trajectories, but their associa‐
tion with the identified classes could be tested after trajectory class 
identification.32 We first performed a univariable analysis studying 
the association between the identified trajectories and each covari‐
ate separately. Afterward, we included all covariates with significant 
interclass differences (P < 0.05) in a multinomial logistic regression 
analyses. Missing data were handled by using the full information 
maximum‐likelihood approach.33 To test for multiple testing, we also 
performed Bonferroni type adjustment on our results. The results 
were presented as odds ratios (OR) with 95% confidence intervals 
(95%‐CI) and corresponding P‐values. Further details regarding the 
statistical analysis are presented in the Supplementary Material S1.
3  | RESULTS
The LGCM model showed poor fit estimates and significant vari‐
ance in growth factors which suggested the appearance of multiple 
classes. The cubic GMM model showed the lowest fit estimates in 
all class models compared to the quadratic and linear models and 
compared to all the LCGA models. Furthermore, the mean value of 
the cubic term was significant in at least one of the classes in the 
cubic term models. We therefore decided on a cubic model with the 
variance for the cubic term fixed to zero.
Goodness of fit statistics for the cubic model with one to five 
classes are presented in Table 1. Fit estimates decreased at progress‐
ing number of classes, and the P‐value for the bootstrap log‐likeli‐
hood test stayed significant.
We decided on the four class model based on a high drop in fit 
estimate values from the three to the four class model and a signifi‐
cant P‐value in the bootstrap likelihood ratio test. Furthermore, the 
four class model revealed important clinical information concerning 
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two classes with a fluctuating course of depressive symptoms which 
were not shown in the two or three class models. We did not choose 
the five class model, since the extra class did not contribute with 
additional clinical important information and one of the classes was 
rather small (5.68%).
The four identified trajectories are presented in Figure 1, and 
the observed individual values within each of the identified classes 
are presented in Figure 2A. The responding class (60.3%) was char‐
acterized by a mean decrease in depressive symptoms during the 
first 8 weeks and then stabilized at a low level throughout the rest 
of the study period (Figure 2A). This group had a mean 78% reduc‐
tion in depressive symptoms and ended up with an average MADRS 
score of 4.5 at the end of follow‐up. We found that 86% of the pa‐
tients categorized into this group had a treatment response (defined 
as a MADRS reduction ≥50%) and 95.9% experienced remission 
(defined as a MADRS score ≤12) at the end of the follow‐up period 
(Figure 2B). The partial‐responding class (18.4%) was characterized 
by an average rapid reduction in depressive symptoms during the 
first 2 weeks followed by a slower decrease throughout 2‐16 weeks 
and an increase between the 16 and 24 weeks. The mean MADRS 
level remained within the level of mild depression at the end of the 
follow‐up (Figure 2A). The partial‐responding class had in average a 
depressive symptom reduction of 33% from baseline to the end of 
the follow‐up period with 27.5% having experienced treatment re‐
sponse and 15.9% experienced remission (Figure 2B). The fluctuating 
class (11.6%) was characterized by a fluctuating course of depressive 
symptoms. The trajectory initial declined, but rebounded to an av‐
erage level of moderate depression after 12 weeks, followed by a 
drop to a level of mild depressive symptoms during the 16‐24 weeks. 
At the end of the follow‐up, the group experienced a mean 58% de‐
crease in depressive symptoms compared to baseline. 66.7% of the 
patients had a treatment response and 52.5% experienced remission 
(Figure 2B). The non‐responding class (9.7%) had a mean MADRS 
score of 29.4 at baseline which increasing even further to 31.4 at 
TA B L E  1   Goodness of fit statistic for one to five class solutions for the cubic GMM analysis
No. of classes
Fit estimatesa P‐valuesb Classification accuracy
Class size (%)iAICc BICd adjBICe Bootstrapf Entropyg Class accuracyh
1 class 25359 25438 25378 — — — —
2 class 25254 25354 25278 <0.001 0.805 0.96 0.89 79.83 20.17
3 class 25224 25345 25253 <0.001 0.802 0.94 0.75 0.85 74.47 6.54 18.98
4 class 25181 25324 25216 <0.001 0.779 0.92 0.91 0.79 0.80 9.74 60.29 18.36 11.60
5 class 25152 25315 25191 <0.001 0.791 0.87 0.91 0.78 0.90 0.81 12.59 58.45 13.41 9.88 5.68
aStatistical information criteria. A lower value indicates a better fit. 
bA significant P‐value indicates that the model with n number of classes is a better t of the data compared to a model with n−1 number of classes 
cAkaike information criteria. 
dBayesian information criteria. 
eSample size adjusted BIC. 
fBootstrap likelihood ratio test. 
gEntropy is estimated based on the average posterior probability and ranges from 0 to 1 where higher estimates represent greater classification accu‐
racy for the model. 
hExpresses the average accuracy of membership classification in each class. As the entropy measure, it ranges from 0 to 1 where higher estimates 
represent greater classification accuracy. 
iDistribution of the total sample into identified classes based on the posterior probability. 
F I G U R E  1   Trajectories of depressive symptoms measured by the MADRS score during 6 months of mood‐stabilizing treatment among 
482 outpatients with bipolar disorder [Colour figure can be viewed at wileyonlinelibrary.com]
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week 24 (ie, a 7% increase). None of the patients in this class experi‐
enced remission or response during the study period.
3.1 | Predictors of class membership
Table 2 presents results from the univariable predictor analysis, and 
Table 3 presents the results from the multivariable predictor analy‐
sis, both using the responding class as the reference. Results from 
the univariable analysis and multivariable analysis using the three 
other classes as references are represented in Supplementary Tables 
S1‐S3 and Supplementary Tables S4‐S6, respectively. Race, employ‐
ment, randomization, current diagnosis of anxiety, history of suicide 
in family, PTSD, psychotic symptoms at baseline, and type of bipolar 
disorder showed significantly interclass differences in the univariable 
predictor analysis (all P < 0.05), and these variables were all included 
in the multivariable analysis. Here, we found that patients diagnosed 
with bipolar disorder type I (vs type II) had more than threefold 
higher odds of membership in the non‐responding class compared 
to the responding class (P = 0.04). People randomized to quetiapine 
treatment, compared to patients randomized to lithium, had lower 
odds of being in the fluctuating (P = 0.006) and partial‐responding 
class (P = 0.023) compared to the responding class and lower odds 
of being in the fluctuating class compared to the non‐responding 
class (P = 0.016); Finally, the presence of psychotic symptoms was 
significantly associated with lower odds of being in the responding 
class compared to the partial‐responding class (P = 0.046). However, 
when using the Bonferroni corrected P‐value, the new critical P‐
value was found by dividing the original α‐value (0.05) with number 
of variables included in the multivariable analysis (8). This means that 
the P value had to be P < 0.00625 to achieve significance. Therefore, 
only randomizing to quetiapine treatment was still significantly asso‐
ciated with lower odds of being in the fluctuating class compared to 
the responding class when using the Bonferroni corrected P‐value.
4  | DISCUSSION
This study is the first to explore the differential trajectories of 
depressive symptoms among outpatients with bipolar disorder 
during 6 months of pharmacotherapy. We used a data‐driven per‐
son‐centered approach and identified a four‐class GMM model, 
which is consistent with what previous trajectory studies have 
found in studies of patients with unipolar depression.16,18,19,34 
We found that 60.3% of the patients were classified into the re‐
sponding class where 96% experienced remission and the average 
MADRS score was 4.5 at the end of the follow‐up. Conversely, 
9.7% of the patients were classified into the non‐responding 
class with moderate to severe depression throughout the entire 
6 months despite medical treatment. No patients in this group re‐
sponded to treatment or had remission. A previous study among 
patients with an acute episode of bipolar disorder used overall 
mood symptoms to estimate trajectories and found that 10.2% 
F I G U R E  2   Presentation of the four identified trajectory classes. (A) Estimated mean trajectories of depressive symptoms measured by 
the MADRS score (bold lines) and the observed individual values within each of the identified classes. The trajectory classes are based on 
“most likely class membership.” (B) Treatment response and remission in the different trajectory classes. All results are presented as valid 
percent, meaning percentage of valid (nonmissing) observations
Partial-responding class Responding class 
Classes a
Treatment response b
n (%)
Remission c
n (%)
Partial-responding 22 (27.5) 13 (15.9)
Fluctuating 26 (66.7) 21 (52.5)
Responding 227 (86.0) 255 (95.9)
Non-responding 0 (0) 0 (0)
a Classes are based on the most likely class membership
b Treatment response is defined as a 50% or higher 
decrease of the MADRS score. Number of missing values 
in each classes (%): Partial-responding 6 (7.0); 
Fluctuating 5 (11.4); Responding 90 (29.2); Non-
responding 4 (9.1);  
c Remission is defined as a MADRS score lower or equal 
to 12. Number of missing values in each class: Partial-
responding 4 (4.7); Fluctuating 4 (9.1); Responding 42 
(13.6); Non-responding  4 (9.1)
Weeks
Non-responding classFluctuating class 
Weeks
M
AD
RS
 sc
or
e
M
AD
RS
 sc
or
e
(A) (B)
     |  355BEHRENDT‐MØLLER ET aL.
TA B L E  2   Predictors for membership of the identified trajectory classes based on the univariable regression analysis. The responding 
class is the reference. Significant findings are bold
Partial‐responding class Fluctuating class Non‐responding class
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age at baseline 1.01 (0.99‐1.04) 0.320 1 (0.97‐1.04) 0.833 1.01 (0.98‐1.04) 0.444
Gender
Female 1.05 (0.55‐2) 0.878 2.25 (0.87‐5.8) 0.093 1.57 (0.76‐3.26) 0.221
Male 1 1 1
Race
All others 1.19 (0.58‐2.46) 0.641 2.43 (1.05-5.64) 0.038 1.11 (0.5‐2.44) 0.803
Caucasian 1 1 1
Education
College or more 0.68 (0.33‐1.37) 0.277 0.77 (0.3‐1.97) 0.589 0.61 (0.29‐1.3) 0.201
High school or 
less
1 1 1
Employment
Not employed 2.08 (1.06-4.08) 0.034 1.73 (0.74‐4.03) 0.203 1.67 (0.82‐3.39) 0.155
Employed/
student
1 1 1
Randomization
Quetiapine 0.46 (0.24-0.89) 0.020 0.25 (0.09-0.66) 0.005 1.06 (0.52‐2.15) 0.871
Lithium 1 1 1
Previous psychiatric hospitalization
Yes 1.49 (0.79‐2.8) 0.217 1.15 (0.51‐2.57) 0.743 1.55 (0.78‐3.07) 0.208
No 1 1 1
Psychotic 
symptoms
1.27 (1.05-1.54) 0.013 1.27 (0.99‐1.61) 0.054 1.23 (1.02-1.46) 0.026
Anxiety
Yes 1.64 (0.84‐3.17) 0.145 1.69 (0.72‐3.97) 0.231 2.59 (1.19-5.65) 0.016
No 1 1 1
Psychiatric illness in family
Yes 1.41 (0.65‐3.05) 0.380 2.27 (0.68‐7.5) 0.181 1.43 (0.62‐3.32) 0.401
No 1 1 1
Suicide in family
Yes 0.79 (0.22‐2.81) 0.713 2.75 (1-7.59) 0.050 1.14 (0.37‐3.52) 0.817
No 1 1 1
Previous suicide attempts
Yes 1.23 (0.64‐2.37) 0.531 1.41 (0.61‐3.23) 0.420 1.85 (0.92‐3.71) 0.083
No 1 1 1
PTSD current
Yes 1.47 (0.53‐4.08) 0.463 2.06 (0.65‐6.52) 0.221 3.62 (1.53-8.6) 0.004
No 1 1 1
Comorbidities
Yes 1.61 (0.84‐3.09) 0.155 0.99 (0.41‐2.43) 0.989 0.91 (0.42‐1.95) 0.802
No 1 1 1
Alcohol abuse within the last 12 mo
Yes 0.38 (0.05‐2.66) 0.332 1.18 (0.3‐4.68) 0.810 1.85 (0.67‐5.11) 0.235
No 1 1 1
(Continues)
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of the population belonged to a group with persistent depressive 
symptoms throughout the 4 weeks study duration.21 However, 
the present study is the first to indicate that approximately one in 
ten outpatients with bipolar disorder have a persistent high level 
of depressive symptoms during 6 months despite state‐of‐the‐art 
pharmacotherapy.
Regarding potential predictors, we found that a higher level of 
psychotic symptoms at baseline was significantly associated with 
lower odds of being in the responding class and that a diagnose 
with bipolar type I predicted membership of the non‐responding 
class compared to the responding class. Finally, we found that sub‐
jects randomized to quetiapine had higher odds of being either in 
the responding class or the non‐responding class compared to the 
fluctuating class and higher odds of being in the non‐responding 
class compared to the partial‐responding class. However, after cor‐
rection with Bonferroni, only the randomization variable showed 
significant interclass differences between the responding class and 
the fluctuating class. These findings may help clinicians to identify 
those patients with additional need for help against persistent de‐
pressive symptoms. The differences between bipolar type I and 
type II support prior studies indicating that type I represents a 
more severe illness course, although other studies have found that 
the burden of depressive symptoms were similar in outpatients 
with bipolar type I and type II.1,5,35 The finding that a higher level 
of psychotic symptoms at baseline was associated with member‐
ship of a trajectory with a worse outcome correspond well with 
the DSM‐IV criteria that assigns psychotic symptoms as a marker 
for illness severity of bipolar disorder. However, the significance 
of psychotic symptoms in relation to clinical outcome in bipolar 
disorder is not yet fully understood. Although some studies have 
found the presence of psychotic symptoms to be associated with 
a higher burden of disease and higher morbidity among patients 
with bipolar disorder type 236, other studies did not find any differ‐
ence in clinical or functional outcome between patients with and 
without psychotic symptoms among patients with bipolar disor‐
der.37,38 Thus, future large studies should elucidate the influence of 
psychotic symptoms on illness development among patients with 
bipolar disorder.
Finally, the found difference between the two treatment arms 
was surprising since the original bipolar CHOICE trial showed that 
treatment with lithium and quetiapine was not significantly different 
overall and the two groups had a similar treatment effect of their 
depression during the 6 months.23 Future studies should in more 
detail and a priori hypotheses investigate whether there may exist 
differences in treatment outcome between quetiapine and lithium in 
specific subgroups and whether subgroups exist that respond bet‐
ter to quetiapine compared to lithium including potential predictors. 
Such a finding would represent clinical important information and 
could eventually help with more personalized medicine in this pa‐
tient group.
5  | STRENGTHS AND LIMITATIONS
The study has several strengths including a large study popula‐
tion and a high inter‐rater reliability.23 Additionally, the frequent 
Partial‐responding class Fluctuating class Non‐responding class
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Alcohol abuse lifetime
Yes 0.97 (0.48‐1.93) 0.923 1.4 (0.6‐3.24) 0.437 1.83 (0.91‐3.68) 0.092
No 1 1 1
Any substance abuse within the last 12 mo
Yes 1.31 (0.52‐3.29) 0.566 1.76 (0.61‐5.11) 0.300 1.67 (0.66‐4.19) 0.277
No 1 1 1
Any substance abuse lifetime
Yes 1.44 (0.76‐2.73) 0.266 1.34 (0.58‐3.05) 0.492 1.78 (0.89‐3.58) 0.105
No 1 1 1
Type of bipolar disorder
Bipolar type I 1.54 (0.75‐3.14) 0.238 1.16 (0.49‐2.77) 0.732 4.04 (1.4-11.65) 0.010
Bipolar type II 1 1 1
CGI mania at 
baseline
1.19 (0.9‐1.56) 0.218 1.07 (0.74‐1.54) 0.728 1.28 (0.99‐1.65) 0.061
Age at first manic 
episode
1.02 (0.98‐1.05) 0.273 1.02 (0.96‐1.07) 0.496 1 (0.96‐1.03) 0.836
Age at first 
depressive 
episode
1 (0.95‐1.05) 0.920 0.99 (0.94‐1.05) 0.780 0.99 (0.95‐1.03) 0.492
TA B L E  2   (Continued)
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assessments of up to 9 visits during 6 month follow‐up allowed us to 
apply a detailed model to identify trajectory groups.
Furthermore, the pragmatic study design with broad inclusion 
and few exclusion criteria results in a high degree of generalizabil‐
ity to outpatients with bipolar disorder seen in everyday clinical 
practice.23
It is important to evaluate the study within its limitations. 
Selection bias may be present since only outpatients who sought 
treatment at academic medical centers were included. Furthermore, 
hospitalization of the patient was an exclusion criterion which 
could potentially exclude those with very severe psychopathology. 
Moreover, the study only had 6 months’ follow‐up, hence, future tri‐
als should explore the extent to which persistent depressive symp‐
toms tend to remit in the longer time perspective and the influence 
of the predictors of the course in the longer run. In this study, we 
did not know for how long the depressive symptoms had been pres‐
ent prior to inclusion time. This is an important limitation since de‐
pressive symptoms can remit spontaneously on their own over time. 
Another limitation concerns the method of GMM. Our choice of the 
model was based on careful statistical and clinical considerations. 
However, the choice of a model in GMM analysis is also a subjective 
assessment and it is possible that others would have found another 
model to be the best fit of the data. Finally, despite the large study 
population, some predictors may not have achieved statistical signif‐
icance due to small trajectory classes.39 This could also be part of the 
reason that many of the found significant predictors were no longer 
significant after the Bonferroni correction.
6  | CONCLUSION
Among 482 adult outpatients with bipolar disorder treated pharma‐
cologically for 6 months, we identified four distinct mood trajectory 
classes. Almost one in ten had persistent high depressive symptoms 
with moderate‐severe depression despite 6 months of pharmacother‐
apy. In the predictor analysis, it was found that psychotic symptoms at 
baseline and bipolar type I predicted membership of trajectories with 
a worse course of depressive symptoms. Finally, the trajectory analy‐
ses also revealed differences between the two randomized treatment 
groups which were not detected by conventional statistical methods.
Future studies with an equal size or larger group of outpatients 
and a longer follow‐up period are needed to explore the heteroge‐
neous course of depressive symptoms in patients with bipolar disor‐
der in more detail. Also it is needed to investigate whether patients 
from the non‐responding class may respond better to additional or 
other treatment regimens.
TA B L E  3   Predictors for membership of the different classes based on the multivariable regression analysis. The responding class is the 
reference. Significant findings are bold
Partial-responding class (18.4) Fluctuating class (11.6) Non-responding class (9.7)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Race
All others 0.97 (0.43‐2.18) 0.942 2.34 (0.89‐6.17) 0.085 0.9 (0.4‐2.04) 0.801
Caucasian 1 1 1
Employment
Not employed 1.72 (0.83‐3.53) 0.142 1.4 (0.52‐3.72) 0.502 1.32 (0.61‐2.82) 0.481
Employed/student 1 1 1
Randomization
Quetiapine 0.44 (0.22-0.89) 0.023 0.23 (0.08-0.65) 0.006 1.02 (0.49‐2.14) 0.949
Lithium 1 1 1
Anxiety
Yes 1.56 (0.76‐3.18) 0.222 1.63 (0.6‐4.42) 0.341 2.04 (0.9‐4.62) 0.087
No 1 1 1
Suicide in family
Yes 0.86 (0.25‐3.02) 0.817 2.92 (0.84‐10.12) 0.091 0.93 (0.27‐3.23) 0.907
No 1 1 1
PTSD current
Yes 0.95 (0.26‐3.44) 0.943 1.38 (0.4‐4.74) 0.612 2.25 (0.88‐5.72) 0.090
No 1 1 1
Type of bipolar disorder
Bipolar type I 0.86 (0.41‐1.83) 0.699 1.29 (0.46‐3.63) 0.624 0.32 (0.11-0.95) 0.040
Bipolar type II 1 1 1
Psychotic symptoms 1.23 (1-1.5) 0.046 1.19 (0.92‐1.54) 0.197 1.08 (0.9‐1.3) 0.387
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Results from this and future studies could be essential to obtain 
a better and more personalized treatment of patients, as previous 
studies show that depressive symptoms remain the greatest chal‐
lenge in the treatment of patients with bipolar disorder.
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